Skip to content
Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
- Whereas, Contractor, acknowledging the relevant socioeconomic impacts, as well as in the Brazilian public health, arising from the Pandemic, shall use its best efforts to anticipate the manufacturing and delivery of the active pharmaceutical ingredient necessary for the production of the vaccine for 2019-nCoV.
- Object and Territory
- 1.3.2 Either during the Pandemic Period or Post Pandemic Period, Fiocruz shall cause all third parties to which Fiocruz sells, distributes or supplies the Finished Vaccine under this Agreement, not to sell, distribute, supply or commercialize the Finished Vaccine in any other manner outside the Territory [the Brazilian public market to meet the needs of SUS], including but without limitation to individuals or to the private market. Furthermore, Fiocruz shall, at its cost and responsibility, create and enforce all necessary for reasonable safeguard arrangements to ensure that none of the Finished Vaccine is sold, distributed, supplied or commercialized outside of the Territory, unless after expansion of the Territory […].